James Eaton is employed as Senior Director Strategic Market Access in our UK office.
James is responsible for the strategic support and overall direction of HE projects globally. He has extensive expertise in the preparation of global value dossiers, core reimbursement dossier, literature reviews, HEOR evidence generation plans, and cost-effectiveness and budget impact modelling. Providing strategic insight into all stages of product development from trial design to the development of value propositions. In addition, James has prepared and directed health technology agency submissions for multiple agencies including NICE, SMC, NCPE and the AWMSG and has supported and participated in over 100 submissions to HTA agencies worldwide including those in the Asia-Pacific and South American regions.
James’ experience includes the reimbursement and market access of pharmaceuticals and medical devices across multiple therapeutic areas, including oncology, diabetes, ophthalmology, haematology, autoimmune diseases, cardiovascular disease, gastroenterology, dermatology and emergency care amongst others. He has presented and chaired meetings and panel sessions on HTA and health economics at national and international conferences including ISPOR, TCT, EuroPCR, RCS and HTAi. James has also authored articles in the BMJ, British Journal of Dermatology, European Heart Journal, OpenHeart, ClinicoEconomics and Outcomes Research amongst others, a full list of publications can be found here: www.researchgate.net/profile/James_Eaton2
James holds a Masters degree in Health Economics from the University of York, and joined Pharmerit from ICON Plc where he was the head of evidence synthesis for the global HE group. Prior to his career as a Health Economist, James spent over 9 years at Pfizer in sales and marketing roles.